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Abstract
Background: Two methods are presented for obtaining hysterectomy prevalence corrected
estimates of invasive cancer incidence rates and probabilities of the corpus uterine.
Methods: The first method involves cross-sectional hysterectomy data from the Utah Hospital
Discharge Data Base and mortality data applied to life-table methods. The second involves
hysterectomy prevalence estimates obtained directly from the Utah Behavior Risk Factor
Surveillance System (BRFSS) survey.
Results: Hysterectomy prevalence estimates based on the first method are lower than those
obtained from the second method through age 74, but higher in the remaining ages. Correction for
hysterectomy prevalence is greatest among women ages 75–79. In this age group, the uncorrected
rate is 125 (per 100,000) and the corrected rate based on the life-table method is 223 using 1995–
97 data, 243 using 1992–94 data, and 228 from the survey method. The uncorrected lifetime
probability of developing corpus uterine cancer is 2.6%; the corrected probability from the life-table
method using 1995–97 data is 4.2%, using 1992–94 data is 4.5%; and based on prevalence data from
the survey method is 4.6%.
Conclusions:  Both methods provide reasonable hysterectomy prevalence estimates for
correcting corpus uterine cancer rates and probabilities. Because of declining trends in
hysterectomy in recent decades, corrected estimates from the life-table method are less
pronounced than those based on the survey method. These methods may be useful for obtaining
corrected uterine cancer rates and probabilities in areas of the world that do not have sufficient
years of hysterectomy data to directly compute prevalence.
Introduction
Conventional cancer incidence rates contain new cases of
the disease for a given year in the numerator and the
mid-year population in the denominator [1]. However,
this rate is potentially problematic for those cancers in
which the denominator includes cases not at-risk of de-
veloping the disease [2]. For example, a large portion of
the female population will undergo a hysterectomy in
their lifetime [2–4], removing them from being at risk of
developing corpus uterine cancer. In addition, a woman
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with cancer of the corpus uterine is very unlikely to be di-
agnosed with the disease a second time [2]. Hence, these
women should be removed from the at-risk population in
the rate calculation.
In the mid 1970s, Lyon and Gardner presented a method
for obtaining hysterectomy prevalence and applied it to
uterine cancers in order to produce corrected incidence
and mortality rates [5]. The approach used the preva-
lence of hysterectomy, as determined by the United
States Health Examination Survey of 1960–1962 [6], and
a cohort model population applied to the 1960 United
States female population. This population was corrected
over time by hysterectomy rates obtained from the Na-
tional Hospital Discharge Survey, a survey providing an-
nual probability samples of hospital discharges from
nonfederal, short-stay hospitals [7]. A more recent study
provided corrected uterine cancer rates for the United
States by applying the method proposed by Lyon and
Gardner and using hysterectomy rates from the National
Hospital Discharge Survey through 1992 [2].
Two other methods may be used to obtain hysterectomy
prevalence estimates that have an advantage in that they
do not require several years of follow-up data to obtain
hysterectomy prevalence estimates. The first involves
calculating hysterectomy prevalence estimates by apply-
ing cross-sectional hysterectomy incidence and all-cause
mortality data to single- and double-decrement life ta-
bles [8]. However, this approach may be limited by
trends in the data. A second approach obtains prevalence
estimates directly from responses to cross-sectional sur-
vey data. An advantage of this method is that it does not
require complicated modeling, but it may be limited by
potential biases that affect self-reported survey data.
The purpose of this paper is to describe these two meth-
ods for correcting corpus uterine cancer incidence rates
and probabilities. The methods yield estimates of the
proportion of the population at risk for developing the
disease and correct the incidence rates and probabilities
accordingly. Although the focus is on corpus uterine can-
cer, the same methods may be applied to other cancers of
the female genital system, such as of the cervix uteri or
ovaries.
Materials and Methods
Method 1. Life-table method of estimating hysterectomy 
prevalence
A single-decrement life table was used to calculate the
proportion (p1x) of a hypothetical cohort of 10 million
newborns alive at the beginning of age interval x when
exposed to the cross-sectional hazard of death from all
causes. From a multiple-decrement life table, the pro-
portion (p2x) of a hypothetical cohort of newborns alive
and at risk of the disease at the beginning of age interval
x is calculated based on their chance of having under-
gone a hysterectomy, having been diagnosed with the
disease, or dying of any cause. Women having undergone
a hysterectomy or previously diagnosed with corpus can-
cer without having had a hysterectomy are assumed to
reflect those not at risk of developing the disease. The
prevalence of having undergone a hysterectomy or hav-
ing been previously diagnosed with corpus uterine can-
cer (minus those having had a hysterectomy is calculated
as Px = 1-(p2x/p1x).
Estimates derived from the life tables represent the prev-
alence that would be observed if a cohort of individuals
were exposed to the current hysterectomy, corpus uter-
ine (minus those having had a hysterectomy), and all-
cause mortality rates over their entire lifetime.
Method 2. Cross-sectional survey method for estimating 
hysterectomy prevalence
The status of an individual with respect to the presence
or absence of a disease or health-related event may be
obtained through assessment at a given point in time.
There are national and international surveys that track
the disease and health status of people in the population.
For example, the Behavior Risk Factor Surveillance Sys-
tem (BRFSS) collects information about women's health
issues, such as pregnancy and hysterectomy. A question
that asks whether a woman has ever had a hysterectomy,
along with solicitation of the woman's current age, indi-
cates the prevalent proportion of women who have had a
hysterectomy by a certain age.
Corrected denominators in the cancer rate calculation
In order to correct the denominator in the rate calcula-
tion of corpus uterine cancer, we need to alter the popu-
lation so that it reflects women at risk of developing the
disease. We assume that a woman is at risk of developing
corpus uterine cancer if she has not already been diag-
nosed with the disease or has had her uterus removed be-
cause of a hysterectomy. The majority of women who are
diagnosed with corpus uterine cancer are treated with a
hysterectomy. The percentage of corpus uterine cancer
cases that underwent a hysterectomy between 1995–97
was 93% overall, 85% for ages 0–39, 98% for ages 40–
59, and 91% for ages 60 and older [9]. Thus, the preva-
lence (Px) derived using the life-table method involves
the age-specific number of hysterectomies plus women
diagnosed with corpus uterine cancer who did not under-
go a hysterectomy (i.e., not at risk). In the survey meth-
od, the age-specific rate of women not at risk of corpus
uterine cancer divided by the age-specific rate of women
having undergone a hysterectomy provided an index
which was multiplied by the age-specific hysterectomy
prevalence obtained from the BRFSS to get an estimateBMC Cancer 2001, 1:13 http://www.biomedcentral.com/1471-2407/1/13
of prevalent proportion of women not at risk of corpus
uterine cancers.
Corrected incidence rates of cancers of the corpus uterine
Conventional cancer incidence rates are derived as Rx=
Cx/Lx, where Cx is the age-specific number of cancer cas-
es and Lx is the mid-year population from cross-sectional
census dat. Corrected rates are derived as:
for x = 0-4, 5-9, . . ., 80-84, 85+.
Lifetime and age-conditional probability estimates
Lifetime and age-conditional probability (risk) estimates
of being diagnosed with cancer are derived using life-ta-
ble methods. Conventional lifetime and age-conditional
probability estimates of being diagnosed with cancer are
corrected for the prevalence of the cancer. This involves
multiplying the cancer incidence rate used in the compu-
tation of the probability estimates by p1x/p2x = 1/(1-Px).
The two methods for obtaining Px are described above. A
complete description of the method for deriving lifetime
and age-conditional probability estimates of being diag-
nosed with cancer is given elsewhere [8]. Probability es-
timates of developing cancer are reported across the age
span and interpreted as the probability that the average
child born today will be diagnosed with the disease by
age x. This statistic assumes that the current rates upon
which the probability estimates are based will remain
constant over the child's lifetime. Given that current
rates are unlikely to remain constant over an extended
period of time, and that persons are more likely interest-
ed in their chance of developing the cancer from their
current ages onward, short-term, age-conditional proba-
bility estimates are perhaps more relevant [10]. Both
types of probability estimates are reported in this paper.
Diagnostic and procedure codes
The Utah Cancer Registry identifies cancer using the In-
ternational Classification of Disease, Second Edition
(ICD-02) [11]. Invasive cancers of the corpus uteri and
other uterus not otherwise specified (hereafter called
corpus uteri) are identified as C540-C549 and C559.
Hysterectomy is defined as International Classification
of Disease, Ninth Revision, Clinical Modification (ICD-
9-CM) procedure codes 68.3 to 68.8, where 68.3 to 68.4
reflect abdominal hysterectomy, 68.5 reflects vaginal
hysterectomy, and 68.6 to 68.8 reflect radical hysterec-
tomy [12].
Data sources
Data from five different sources were used in the analy-
sis: hysterectomy cases obtained from the Hospital Dis-
charge Data Base (HDDB) in Utah, hysterectomy
prevalence obtained from the BRFSS, invasive corpus
uterine cancer cases from the Utah Cancer Registry, pop-
ulation estimates from the United States Bureau of the
Census, and mortality data from the Utah State Health
Department. Population estimates of the female resi-
dents in Utah were combined with case data to compute
hysterectomy incidence rates, prevalence proportions,
and invasive cancer incidence rates and probabilities.
Three years of data were considered in order to provide
more stable estimates. The influence of race was not con-
sidered because of the high percentage of whites in Utah








Table 1: Numbers and crude rates of hysterectomy per 100,000 women in Utah during 1992–94 and 1995–97
1992–94 1995–97
Age Group Number Rate Number Rate
15–24 287 57 212 36a
25–34 3,568 838 2,910 664ab
35–44 6,138 1597 6,232 1494ab
45–54 3,679 1455 3,990 1328a
55–64 1,145 636 1,224 624
65–74 834 547 807 512
75+ 373 288 411 287
15+ 16,024 788 15,786 705a
Data source: Utah Hospital Discharge Data, Public Dataset. aSignificant change in rates between 1992–94 and 1995–97, p < 0.05.BMC Cancer 2001, 1:13 http://www.biomedcentral.com/1471-2407/1/13
Fifty-five Utah hospitals submit data to the Utah Health
Data Committee on an ongoing basis. These hospitals in-
clude nine psychiatric facilities, seven specialty hospi-
tals, and the Veterans Administration Medical Center.
Shriners Hospital, a charity hospital, is exempt from re-
porting requirements. These hospitals report discharge
data (i.e., the consolidation of complete billing, medical,
and personal information describing a patient, the serv-
ices received, and the charges billed) for each patient
served on an inpatient basis.
Cancer data were obtained from the Utah Cancer Regis-
try, which is one of the oldest in the country, originating
in 1966. Since 1973, the Utah Cancer Registry has partic-
ipated in the Surveillance, Epidemiology, and End Re-
sults (SEER) Program of the National Cancer Institute
[1]. The registries in the SEER Program meet high-qual-
ity standards and are the nation's source of cancer inci-
dence and survival data. Since 1983, the cancer registries
in the SEER Program have also collected first course of
cancer-directed therapy. The Utah Cancer Registry en-
sures complete incidence and treatment information by
abstracting information from hospital records, clinical
and nursing home records, private pathology laborato-
ries and radiotherapy units, and death certificates.
The BRFSS is a state-based surveillance system active in
all 50 states. Since the early 1980s, the Center for Disease
Control and Prevention has collaborated with states to
develop questions that would reveal adults' knowledge,
attitudes, and practices related to health issues. Since
1984 Utah has been involved in collecting data for the
BRFSS.
Age-specific corpus uterine rates are fit using second- or
third-order polynomial models.
Results
Numbers and crude rates of hysterectomy per 10,000 in
Utah are shown for 1992–94 and 1995–97 (Table 1). The
rates increase early in life, peak, and then decrease over
the older ages. The rates were significantly higher in
1992–94, compared to 1995–97, in the age groups 25–34
and 35–44. Estimates of hysterectomy prevalence based
on the life-table method and the survey method are pre-
sented in Figure 1. Higher prevalence estimates based on
the life-table method with 1992–94 data versus 1995–97
data reflect lower hysterectomy rates in the later time pe-
riod for most ages. Prevalence estimates based on the
BRFSS 1995–97 are highest, particularly for women aged
45 through 69.
During 1995–97, there were 549 cases of invasive cancer
of the corpus uteri in Utah. The age-adjusted rate was 20
per 100,000. This conventionally derived rate is based
on the denominator of the rate calculation including
women who are not at risk of being diagnosed with inva-
sive cancer of the corpus uterine. Figure 2 presents cor-
rected and uncorrected population denominators with
the corrections based on the two methods. Applying the
corrected populations, the age-adjusted rates using the
life - table method became 32 with 1995-97 data, 34 with
1992-94 data, and using the survey method was 37.
Figure 3 presents corrected and uncorrected invasive
cancer incidence rates of the corpus uteri in Utah. The
correction for hysterectomy prevalence was greatest
among women ages 75–79. In this age group, the uncor-
rected rate was 125 per 100,000 and the corrected rate
using the life-table method was 223 based on 1995–97
data, 243 based on 1992–94 data, and the corrected rate
using the survey method was 228.
The lifetime probability of developing corpus uterine
cancer was 2.6% (uncorrected); and corrected, based on
the life-table method, was 4.2% using 1995–97 data,
4.5% using 1992–94 data; and according to the survey
method was 4.6%. Corresponding percentages women
free of the disease at age 50 are slightly lower, 2.5%,
4.1%, 4.4%, and for 4.5%.
Figure 1
Age-specific hysterectomy point prevalence proportions in
Utah according to calendar year and sourceBMC Cancer 2001, 1:13 http://www.biomedcentral.com/1471-2407/1/13
Table 2 shows the corrected and uncorrected number per
100,000 invasive cancers of the corpus uteri expected in
Utah over the next 10 years among women aged x. Ten-
year probability estimates are largely influenced by the
age in which they are conditioned. The 10-year probabil-
ity of being diagnosed with cancer of the corpus uterine
is greatest for women aged 65. The corrections increase
these probabilities considerably, most noticeably for
those corrected using the survey method.
Discussion
This paper presents two methods for obtaining corrected
corpus uterine cancer incidence rates and probabilities.
In the life-table method, hysterectomy or corpus uterine
cancer prevalence estimates were derived from cross-
sectional hysterectomy, corpus uterine, and all-cause
mortality data applied to life tables. In the survey meth-
od, hysterectomy prevalence estimates were obtained di-
rectly from BRFSS data. The purpose of the correction
was to adjust the population values used in the calcula-
tions in order to reflect the at-risk population for devel-
oping corpus uterine cancer.
Both methods have the advantage that several years of
follow-up data are not required to determine the at-risk
population. Hence, for areas of the world that do not
have sufficient years of hysterectomy or cancer data to
directly compute prevalence, corrected rates and proba-
bilities can still be obtained. However, the life-table
method is limited by trends in the data. Because the hys-
terectomy rates were lower in 1995–97 than in previous
years, the prevalence estimates based on these years un-
derestimated the prevalence of this procedure. Use of the
higher incidence rates in 1992–94 produced higher hys-
terectomy prevalence estimates across the age span.
However, prevalence based on these rates may also have
been underestimated, at least through ages 69, as sug-
gested by the hysterectomy prevalence estimates from
the survey method.
According to a self-reported national survey, hysterecto-
mies have remained stable between 1965–95 [14]. How-
ever, based on the National Hospital Discharge Survey,
there is evidence that hysterectomy rates decreased
slightly from the mid 1970s through the 1980s and then
may have leveled off through 1993 [4,15,16]. Our results
show that hysterectomy in Utah significantly decreased
between 1992–94 and 1995–97 in the age groups 25–34
and 35–44, where hysterectomy is most common. This
Figure 2
Corrected and uncorrected population denominators
Figure 3
Corrected and uncorrected invasive cancer incidence of the
corpus uteri and uterus not otherwise specified in UtahBMC Cancer 2001, 1:13 http://www.biomedcentral.com/1471-2407/1/13
suggests that hysterectomy prevalence based on the
cross-sectional method, at least for ages less than 55
based on 1995-97 data, underestimates hysterectomy
prevalence. Use of the survey method to obtain preva-
lence has the advantage that it does not require compli-
cated modeling and is not influenced by trends, but it
may or may not represent the Utah population, given po-
tential biases that may influence self-reported responses.
Yet a high level of correspondence has been previously
shown to exist between self-reports and hospital records
of hysterectomy [17].
In an earlier report by Merrill and Feuer [2], based on
1990–92 national data, the hysterectomy prevalence
correction based on an historical, rather than a cross-
sectional, approach increased the age-adjusted rates of
corpus uterine rates from 22.2 to 33.0. Although we can-
not compare our results directly because of difference in
time periods studied, the unique racial makeup in Utah,
and because we also incorporated the prevalence of cor-
pus uterine cancer cases not treated with a hysterectomy,
the magnitude of the correction is similar to those re-
ported in this prior study.
As anticipated, the hysterectomy prevalence corrections
had large influences on the rates and probabilities. The
percentage increase was smallest earlier in life and in-
creased consistently with age. This is because the
number of women alive that have undergone a hysterec-
tomy increases over the age span, as evident in the cor-
rected versus the uncorrected rates and probabilities.
Yet, although the percentage change increases with age,
the greatest absolute change tends to be where the cancer
rates are largest.
It should be emphasized that correcting the rates and
probabilities had a large impact because of the high prev-
alence of hysterectomy. The additional influence of prev-
alent cases of corpus uterine cancer cases who had not
undergone a hysterectomy was relatively very small. Sev-
eral studies have explored the benefits, risks, and costs of
hysterectomy [18–28]. Despite the potential risks and
costs associated with this medical procedure, over 35%
of women in the United States received a hysterectomy
by age 50 [2]. Hysterectomies are primarily performed
for nonmalignant conditions [3,4], with the expectation
that the benefits of the surgery outweigh the risks.
Given the high percentage of whites in Utah, the study
results primarily reflect this race. Hence, comparison of
the results to other geographic locations should be re-
stricted to primarily white populations. Yet the results
provide an important baseline for future comparisons.
In addition to the limitations stated above, because it is
impractical to expect cross-sectional rates upon which
lifetime and age-conditional cancer probabilities are
based to remain constant in the long run, lifetime proba-
bilities of cancer are less reliable than shorter term, age-
conditional probability estimates. They are also less rel-
evant to a woman already aged to mid-life. However, life-
time probability estimates of cancer may provide a guide
to individuals and health policy officials as to the burden
of these select cancers.
Table 2: Corrected and uncorrected number per 100,000 of invasive cancers
Age x
25 35 45 55 65
Uncorrected
Number 208 464 680 774 885
Life Table Method 1995–97
Number 276 677 1,037 1,243 1,480
% Increase a 32.7% 45.9% 52.5% 60.6% 67.2%
Life Table Method 1992–94
Number 289 721 1,109 1,334 1,595
% Increase a 38.9% 55.4% 63.1% 72.4% 80.2%
Survey Method 1995–97
Number 345 876 1,336 1,586 1,633
% Increase a 65.9% 88.8% 96.5% 104.9% 84.5%
aPercentage increase between the corrected and uncorrected number of invasive corpus uteri and uterus not otherwise specified.BMC Cancer 2001, 1:13 http://www.biomedcentral.com/1471-2407/1/13
As already well established, an accurate representation
of the expected risk of corpus uterine cancer requires
that the population in the incidence-rate calculation be
corrected to reflect the at-risk population. Similarly, an
accurate measure of the burden of this cancer, in terms
of lifetime and age-conditional probabilities of develop-
ing the disease, also requires a population correction to
reflect those women at risk. The two methods developed
in this study reflect unique strengths and weaknesses.
Yet despite their potential weaknesses and in the absence
of long-term hysterectomy and cancer data, they will
provide more reasonable estimates of the rates and prob-
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